FHTX Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of 20.1%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.75, signalling upside risk potential of 156.55%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 5.77%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,934.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 11.42x versus 19.09x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of --. Foghorn Therapeutics, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.75, signalling upside risk potential of 156.55%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 575.68%. Given that CEL-SCI Corp. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Foghorn Therapeutics, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than CEL-SCI Corp. quarterly revenues of --. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 11.42x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -953.4%. Foghorn Therapeutics, Inc.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.75, signalling upside risk potential of 156.55%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1125.09%. Given that IGC Pharma, Inc. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Foghorn Therapeutics, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 11.42x versus 22.97x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -255.85%. Foghorn Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Foghorn Therapeutics, Inc. has a consensus price target of $11.75, signalling upside risk potential of 156.55%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Foghorn Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 11.42x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.